ArticleInternational cancer conference journal2026
An exceptionally late and severe radiation recall dermatitis with chest-wall ulceration 32 years after breast radiotherapy: a case report and literature review.
Article in International cancer conference journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation recall phenomenon (RRP) is an inflammatory reaction occurring in previously irradiated tissues after exposure to certain drugs, and very late-onset cases are exceptionally rare. We report a 58-year-old woman with Human Epidermal Growth Factor Receptor 2 (HER2)-positive, estrogen receptor (ER) / progesterone receptor (PgR)-positive invasive ductal carcinoma of the left breast who had undergone contralateral mastectomy and radiotherapy 32 years earlier. During neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab, she developed rapidly progressive ulceration and necrosis confined to the prior radiation field on the right chest wall. Docetaxel and carboplatin were discontinued while trastuzumab and pertuzumab were continued. Intensive dermatologic management, including repeated surgical debridement and topical therapy, was required, and substantial epithelialization was achieved only after an approximately two-year course, highlighting a protracted recovery. The clinical course was considered most consistent with severe late-onset radiation recall dermatitis (RRD) superimposed on chronically vulnerable irradiated tissue. Clinicians should consider RRD during systemic therapy in patients with a history of radiotherapy, even decades after treatment, and should distinguish it from chronic radiation injury, infection, and recurrent cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.